Second-Generation Cephalosporins-Associated Drug-Induced Liver Disease: A Study in VigiBase with a Focus on the Elderly
- PMID: 34067178
- PMCID: PMC8151124
- DOI: 10.3390/ph14050441
Second-Generation Cephalosporins-Associated Drug-Induced Liver Disease: A Study in VigiBase with a Focus on the Elderly
Abstract
Background: The objective of this study was to characterize individual case safety reports (ICSRs) and adverse drug reactions (ADRs) related to second-generation cephalosporins and resulting in hepatobiliary disorders, in VigiBase, WHO global database.
Methods: All second-generation cephalosporins hepatobiliary ADRs reported up to July 2019 were included. Characteristic of cephalosporins and ADRs, aside from disproportionality data were evaluated.
Results: A total of 1343 ICSRs containing 1585 ADRs were analyzed. Cefuroxime was suspected to have caused hepatobiliary disorders in most cases-in 38% of adults and in 35% of elderly. Abnormal hepatic function was the most frequent ADR, followed by jaundice and hepatitis. For 49% of the ADRs reported in the elderly and 51% in the adult population, the outcome was favorable, with fatal outcome for 2% of the adults and 10% of the elderly. Higher proportional reporting ration (PRR) values were reported in the elderly for cefotetan-associated jaundice, cefuroxime-associated acute hepatitis and hepatitis cholestatic as well as for cefotiam and cefmetazole-associated liver disorder.
Conclusion: Hepatobiliary ADRs were reported for 2nd generation cephalosporins, with over 50% of cases in adults, without gender differences. Cholestatic hepatitis was predominately reported in the elderly and this category was more prone to specific hepatic reactions.
Keywords: VigiBase; adverse drug reaction; cephalosporins; hepatotoxicity.
Conflict of interest statement
The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
Figures
Similar articles
-
Adverse drug reactions of statins in children and adolescents: a descriptive analysis from VigiBase, the WHO global database of individual case safety reports.Fundam Clin Pharmacol. 2020 Aug;34(4):518-520. doi: 10.1111/fcp.12542. Epub 2020 Mar 10. Fundam Clin Pharmacol. 2020. PMID: 32022302
-
Analysis of Hepatobiliary Disorder Reports Associated With the Use of Herbal Medicines in the Global Suspected ADR Database Vigibase.Front Pharmacol. 2019 Nov 6;10:1326. doi: 10.3389/fphar.2019.01326. eCollection 2019. Front Pharmacol. 2019. PMID: 31780942 Free PMC article.
-
Suspected cutaneous adverse drug reactions reported with traditional medicines: analysis of data for United Nations Asia region from WHO VigiBase.Front Pharmacol. 2023 May 30;14:1088841. doi: 10.3389/fphar.2023.1088841. eCollection 2023. Front Pharmacol. 2023. PMID: 37324461 Free PMC article.
-
Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.Health Technol Assess. 2011 May;15(20):1-234, iii-iv. doi: 10.3310/hta15200. Health Technol Assess. 2011. PMID: 21545758 Review.
-
Database size and power to detect safety signals in pharmacovigilance.Expert Opin Drug Saf. 2007 Nov;6(6):713-21. doi: 10.1517/14740338.6.6.713. Expert Opin Drug Saf. 2007. PMID: 17967160 Review.
Cited by
-
Drug-Induced Liver Injury in Hospitalized Patients during SARS-CoV-2 Infection.Medicina (Kaunas). 2022 Dec 15;58(12):1848. doi: 10.3390/medicina58121848. Medicina (Kaunas). 2022. PMID: 36557050 Free PMC article. Review.
-
Safety evaluation of ceftazidime/avibactam based on FAERS database.Infection. 2024 Dec;52(6):2195-2205. doi: 10.1007/s15010-024-02248-3. Epub 2024 Jun 6. Infection. 2024. PMID: 38842750
References
-
- Bui T., Preuss C. Cephalosporins. StatPearls Publishing LLC; Treasure Island, FL, USA: 2020. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials